US4544664A - Antihypertensive substituted imidazole derivatives - Google Patents

Antihypertensive substituted imidazole derivatives Download PDF

Info

Publication number
US4544664A
US4544664A US06396000 US39600082A US4544664A US 4544664 A US4544664 A US 4544664A US 06396000 US06396000 US 06396000 US 39600082 A US39600082 A US 39600082A US 4544664 A US4544664 A US 4544664A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
ch
imidazole
formula
α
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US06396000
Inventor
Arto J. Karjalainen
Kauko O. A. Kurkela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Corp
Original Assignee
Farmos-Yhtyma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/63Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/69Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by addition to carbon-to-carbon double or triple bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/72Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
    • C07C45/74Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups combined with dehydration
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/213Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C49/217Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

The invention provides novel compounds of the formula: ##STR1## wherein the various substituents are defined herein below. Processes for the preparation of these compounds are described, as are novel pharmaceutical compositions comprising at least one of the compounds of their salts. The compounds and their non-toxic salts exhibit valuable pharmacological activity and are useful in the treatment of mammals, especially as antihypertensive agents. Furthermore, some of the compounds have proved to possess antithrombotic and diuretic activity. Antimycotic and antifungal properties have also been found.

Description

DESCRIPTION

The present invention relates to substituted imidazole derivatives and their non-toxic, pharmaceutically acceptable acid addition salts, and their preparation, to pharmaceutical compositions containing the same, and to their use.

The imidazole derivatives of the present invention have the general formula: ##STR2## wherein R1 is H, an alkyl of 1 to 4 carbon atoms, e.g. methyl or --CH2 OH; R2 is H or CH3 ; R3 is --CH3, --CH2 CH3, --CH2 CH2 CH3, ##STR3## --CH2 CH2 CH2 CH3, --CH2 CH═CH2, or ##STR4## and R4 is H or OH; or R3 and R4 together represent ═CH2, ═CH--CH3, ═CH--CH2 --CH3, ##STR5## or ═CH--CH2 CH2 CH3 ; X is ##STR6## R5, R6, and R7, which can be the same or different are H, --CH3, --CH2 CH3, halogen, OH or --OCH3 or R5 is hydrogen and R6 and R7 together form an --O--CH2 --O--bridge between two adjacent carbon atoms in the phenyl group; --CHR8 -- is --CH2 --, --CH(CH3)--, --CH(--CH2 CH3)--, --CH(--CH2 CH2 CH3)--, ##STR7## --CH(--CH2 CH2 CH2 CH3)-- or >C═CH2, >C═CH--CH3, >C═CH--CH2 CH3, ##STR8## >C═CH--CH2 CH2 CH3 ; R9 is H, --CH3, --CH2 CH3, --CH2 CH2 CH3, ##STR9## --CH2 CH2 CH2 CH3 or OH; R10 is H, --CH3, --CH2 CH3, --CH2 CH2 CH3, ##STR10## or --CH2 CH2 CH2 CH3 ; R11 is H, --CH3, --CH2 CH3, --CH2 CH2 CH3, ##STR11## or --CH2 CH2 CH2 CH3 ; n is 0 to 4; provided that

when R4 is OH, R1 is H or CH3 and R3 is ##STR12##

then R5, R6 and R7 are not all simultaneously hydrogen;

when R1, R2 and R4 all are hydrogen and R3 is ##STR13##

then R5, R6, R7 are not all simultaneously hydrogen;

R8 and R9 are not simultaneously hydrogen; and

R11 and R10 are not simultaneously hydrogen.

Because of the tautomerism in the imidazole ring the compounds of the general formula I and II are 4(5)-substituted imidazole derivatives.

The non-toxic pharmaceutically acceptable acid addition salts of these compounds are also within the scope of the invention.

The compounds of the formula (I) and (II) form acid addition salts with both organic and inorganic acids. They can thus form many pharmaceutically usable acid addition salts, as, for instance, chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, citrates, benzoates, salicylates, ascorbates and the like.

The invention includes within its scope pharmaceutical compositions comprising at least some of the compounds of formula (I) or (II) or a non-toxic, pharmaceutically acceptable salt thereof, and a compatible pharmaceutically acceptable carrier therefor.

The invention provides, for example, the following specific compounds of formula (I):

4-[α,α-bis(2-methylphenyl)hydroxymethyl]imidazole

4-[[α-(2-methylphenyl)]-2-methylbenzyl]imidazole

4-(α-phenylbenzyl)-5-methylimidazole

4-[[α-(2,6-dimethylphenyl)]-α-methyl]hydroxymethyl]imidazole

4-[[α-(2,3-dimethylphenyl)]-α-methyl]hydroxymethyl]imidazole

4-[α,α-bis(2-methylphenyl)hydroxymethyl]-5-methylimidazole

4-[[α-(2-methylphenyl)]-2-methylbenzyl]-5-methylimidazole

4-[(α-methyl)-2,6-dimethylbenzyl]imidazole

4-[(α-methyl)-2,3-dimethylbenzyl]imidazole

4-[(α-ethyl)-3-methylbenzyl]imidazole

4-[(α-butyl)-2,3-dimethylbenzyl]imidazole

4-[(α-methyl)-2,3-dimethylbenzyl]-2-methylimidazole

4-[(α-propyl)-2-methylbenzyl]imidazole

4-[(α-methyl)-2-methylbenzyl]imidazole

4-[(α-methyl)-2,5-dimethylbenzyl]imidazole

4-[α-ethyl-α-(3-methylphenyl)-hydroxymethyl]imidazole

4-[α-butyl-α-(2,3-dimethylphenyl)-hydroxymethyl]imidazole

4-[α-methyl-α-(2,3-dimethylphenyl)-hydroxymethyl]-2-methylimidazole

4-[α-propyl-α-(2-methylphenyl)-hydroxymethyl]imidazole

4-(α-methyl-2-chlorobenzyl)imidazole

4-[α-methyl-α-(2-methylphenyl)-hydroxymethyl]imidazole

4-[α-methyl-α-(2,5-dimethylphenyl)-hydroxymethyl]imidazole

4-[α,α-bis-(2,3-dimethylphenyl)hydroxymethyl]imidazole

4-[α-(2,3-dimethylphenyl)-2,3-dimethylbenzyl]imidazole

4-[(α-ethyl)-2,6-dimethylbenzyl]imidazole

4-[(α-ethyl)-2,3-dimethylbenzyl]imidazole

1-(4-imidazolyl)-1-(2,3-dimethylphenyl)ethylene

1-(4-imidazolyl)-1-(2,6-dimethylphenyl)ethylene

1-(4-imidazolyl)-1-(2,3-dimethylphenyl)propene

1-(4-imidazolyl)-1-(2,3-dimethylphenyl)pentene

The following specific compounds of formula (II):

4-[2-(2,6-dimethylphenyl)-1-methylethyl]imidazole

4-[2-(2,6-dimethylphenyl)propyl]imidazole

4-[2-(2,3-dimethylphenyl)propyl]imidazole

4-[2-(2,6-dimethylphenyl)-1-methylpropyl]imidazole

4-[2-(2,6-dimethylphenyl)-2-hydroxyethyl]imidazole

4-(2-phenylpropyl)imidazole

4-[2-(2,6-dimethylphenyl)-1-methylethenyl]imidazole

4-[2-(2,6-dimethylphenyl)-1-propenyl]imidazole

4-(2-methyl-4-phenyl-1-butenyl)imidazole

4-[2-(4-chlorophenyl)-1-methylpropyl]imidazole

4-[5-(2,6-dimethylphenyl)-1-methyl-1-pentenyl]imidazole

4-[3-(2,6-dimethylphenyl)-2-methyl-1-propenyl]imidazole

4-[2-(2,6-dimethylphenyl)-1-ethylethenyl]imidazole

4-[2-(2,3-dimethylphenyl)-1-methylethenyl]imidazole

4-[2-(2,6-dimethylphenyl)-1-isopropylethenyl]imidazole

4-[2-(2,6-dimethylphenyl)-1-methylethenyl]-2-methylimidazole

4-[2-(2,6-dimethylphenyl)-1-methylethenyl]-5-methylimidazole

4-[2-(2,6-dichlorophenyl)-1-methylethenyl]imidazole

4-[5-(2,6-dimethylphenyl)-1-methyl-1-pentenyl]imidazole

4-[3-(2,6-dimethylphenyl)-1-ethyl-1-propenyl]imidazole

4-[5-(2,6-dimethylphenyl)-1-methyl-1-pentenyl]-5-methylimidazole

4-[5-(2,6-dimethylphenyl)-1-methylpentyl]imidazole

4-[4-(2,6-dichlorophenyl)-1-methyl-1-butenyl]imidazole

4-[2-(2,6-dimethylphenyl)-1-ethylethyl]imidazole

4-[2-(2,6-dimethylphenyl)-2-ethylethyl]imidazole

4-[2-(3,4-methylenedioxyphenyl)propyl]imidazole

4-[2-(2-bromo-4,5-methylenedioxyphenyl)propyl]imidazole

The compounds of the present invention have been found to possess excellent antihypertensive activity. Preliminary tests have shown that they also possess other valuable pharmacological properties, for example, antithrombotic and diuretic effect. Antimycotic and antifungal properties have also been found.

While all of the compounds of formula (I) and (II) essentially satisfy the objectives of the present invention, certain groups of compounds remain preferred. One such preferred group is represented by formula (I) wherein R4 is hydrogen, R3 is alkyl and R5, R6 and R7, which can be the same or different, each are hydrogen, methyl, ethyl or halogen. Another preferred group of compounds is represented by formula (II), wherein R5, R6 and R7, which can be the same or different, each are hydrogen, methyl, ethyl or halogen. In such compounds, those in which R1 is hydrogen or methyl, R2 is hydrogen or methyl, R8 or R11 is methyl, ethyl or isopropyl, R9 and R10 are hydrogen and n is 0 may be mentioned. Especially the compounds wherein n is greater than 0 possess valuable antimycotic properties. Especially good antihypertensive properties have been found in compounds of formula (II) wherein n is 0 and X is ##STR14##

According to the feature of the invention, the compounds of formula (I) wherein R4 is OH and the compounds of formula (II) are made by a Grignard reaction, in which an imidazolylketone of the formula ##STR15## wherein R1, R2 and R3 are as defined before, is reacted with an arylalkyl magnesium halide derivative or aryl magnesium halide derivative of the formula: ##STR16## wherein R5, R6 and R7 are as defined before, n' is 0 to 5 and Hal is a halogen atom to give compounds of the formula (III) ##STR17## wherein R1, R2, R3, R5, R6, R7 and n' are as before.

The arylalkylmagnesium halide derivative can be, for example, an arylalkylmagnesiumbromide derivative, which is prepared by reacting the corresponding arylalkylbromide derivative with magnesium. Suitable solvents for the reaction include a variety of ethers, preferably tetrahydrofuran. The arylalkylmagnesiumhalide derivative is prepared in the usual way by adding the arylalkylmagnesiumhalide derivative in a suitable solvent, e.g. tetrahydrofuran, dropwise onto magnesium turnings covered by tetrahydrofuran, at the boiling point of the reaction mixture. When the magnesium turnings have reacted, the mixture is cooled slightly and the 4-imidazole derivative is added in solid form in small portions or in tetrahydrofurane solution. After the addition, the reaction mixture is refluxed until all of the 4-imidazole derivative has reacted. The reaction time varies between one and five hours.

Another process for the preparation of compounds of formula (III) is a Grignard reaction in which a compound of the formula (IV) ##STR18## wherein R1 -R7 and n' are as before, is reacted with a compound of the formula

R.sub.3 MgHal

wherein R3 is an alkyl or aryl as defined before and Hal is halogen. Yet another process for the preparation of compounds of formula (III) is a Grignard reaction in which an imidazole carboxylic acid alkyl ester, preferably the methyl ester of the formula ##STR19## wherein R1 and R2 are as before, is reacted in a first step/with a Grignard reagent of the formula ##STR20## wherein R5, R6, R7 and n' are as before, to give a compound of formula (IV), which in a second step without isolation is reacted with a Grignard reagent of the formula

R.sub.3 MgHal

wherein R3 is as defined before.

Compounds of formula (I) wherein R4 is H can be prepared by reduction of compounds of formula (III) wherein n' is 0 with hydrogen. A suitable catalyst is e.g. palladium-on-carbon.

Unsaturated compounds of formula (I) wherein R3 and R4 are ═CH2, ═CH--CH3, ═CH--CH2 CH3, ##STR21## or ═CH--CH2 CH2 CH3 or formula (II) wherein R10 is hydrogen are prepared by dehydrating compounds of formula (III): ##STR22## wherein R1, R2, R5, R6, R7 are as defined before, R3 is an alkyl or aryl as defined before and n' is 0 to 5, to give a compound of the formula (V) ##STR23## wherein R1, R2, R5, R6, R7, and n and n' are as defined before; R11 is an alkyl as defined before and R8 is an alkenyl as defined before.

The dehydration is preferably performed by refluxing in an appropriate acidic solution, e.g. concentrated hydrochloric acid or heating for example with potassiumhydrogen sulfate.

The compounds of formula (V) can further be reduced with hydrogen in the presence of a palladium-on-carbon catalyst to the corresponding saturated compounds of formulae (I) and (II).

Compounds of formula (II) wherein R11 is hydrogen are prepared by a Wittig reaction which comprises reacting an imidazole aldehyde of the formula ##STR24## wherein R1 and R2 are as before, with an aralkylidenetriphenylphosphorane of the formula: ##STR25## wherein R5, R6, R7, R10 and n are as defined before, to give the unsaturated compounds of formula (II), which in a further step can be reduced to the corresponding saturated compounds of formula (II) as described above.

The aralkylidenetriphenylphosphoranes are preferably prepared by reacting the corresponding aralkyltriphenylphosphonium halide of the formula: ##STR26## wherein R5, R6, R7, R10 and n are as before and Hal is halogen, with a basic reagent, preferably butyllithium.

In the Grignard- and Wittig-syntheses described above, the free nitrogen atom in the imidazole starting material can be protected by different methods. Suitable protecting groups are for example benzyl, triphenylsilyl or dialkoxymethane. The removal of the protecting group can be performed in different ways, and depends on the kind of protecting group used. For example, a dialkoxymethane group is removed by acidic hydrolysis and a benzyl group by sodium in liquid ammonia.

The present invention further provides yet another method for preparing compounds of the invention. Thus, according to this embodiment of the invention, a starting material of the formula (VI) or (VII) ##STR27## wherein R2, R3, R5, R6, R7 and n are as hereinbefore defined; wherein R12, R13, R14 and R15, which can be the same or different, are each hydrogen, hydroxy, mercapto, halogen, amino, --O-- alkyl of 1 to 7 carbon atoms or ##STR28## wherein R is an alkyl; or wherein R12 and R14 can be combined to form a keto group, or R13 and R15 can be combined to form a keto group, or both R12 and R14 and R13 and R15 can simultaneously form keto groups; is reacted with a reagent capable of converting said starting material to the corresponding imidazole of the formula: ##STR29## wherein R1, R2, R3, R5, R6, R7, X and n are defined as before. Reagents capable of converting the depicted starting material to the corresponding imdidazole include NH3 +CH2 O (or a source of ammonia and formaldehyde); ##STR30## or R1 CHO and NH3. Choice of an appropriate reagent varies with the particular starting material employed.

When R1 is hydrogen it is preferable to employ formamide as the reagent in cases where, in place of the bromine atom in the aforementioned starting materials, there is instead a hydroxyl, amino or acetyl group. In these instances, formamide is used in excess and acts in part as the solvent. Generally, the reaction is run at the boiling point of formamide for a period of time ranging from one to five hours.

Yet another process for the preparation of the compounds of formula (I) and (II) comprises reacting formamide with a benzene derivative of the formula: ##STR31## wherein R5, R6, R7, R8, n and X are as defined hereinabove, and Q is a radical of formula: ##STR32## wherein R is a substituted and unsubstituted alkyl, arylalkyl or aryl group, and R2, and Hal are as defined hereinabove. Preferably the reaction is performed by vigorously boiling the benzene derivative in formamide, the reaction time varying with the particular material employed.

Reaction times typically are from 30 minutes to 8 hours. Obviously, the formamide treatment will be followed by reaction with an appropriate acid (e.g. HCl) when Q in the starting material is ##STR33## in order to obtain the corresponding compound of formula (I) and (II).

Similarly, when a starting material wherein Q is ##STR34## is employed, then the formamide treatment will be followed by hydrogenation, thus affording the desired compound of formula (I) and (II).

A further process for the preparation of the compounds of the formula (I) and (II) comprises hydrolysing a corresponding N-acetylated compound of the formula (I) and (II) ##STR35## where Y is the arylalkylresidue determined by the formula (I) and (II), R is an alkyl group of 1 to 7 carbon atoms or an aryl radical of 6 to 10 carbon atoms.

Preferably, the hydrolysis is carried out by boiling the starting material, an N-acylated imidazole derivative, in an aqueous solution of an inorganic acid until the reaction is completed.

Yet another process for the preparation of the compounds of formula (I) and (II) comprises hydrogenating a starting material of the formula: ##STR36## wherein Y is as defined before and R' is an aryl or alkyl and R" is an aryl group. The hydrogenation is conveniently conducted in the presence of a suitable catalyst and under a hydrogen atmosphere, with stirring or using metallic sodium in liquid ammonia. Suitable catalysts include platinum oxide, palladium-on-carbon and Raney nickel. Reaction temperatures vary with the particular starting material employed, with typical temperatures being 25°-70° C.

Yet another method for the preparation of the compounds of formula (I) or (II) wherein X is ##STR37## comprises reacting a N-trialkylsilylimidazole of the formula ##STR38## wherein Y is an alkyl group, preferably methyl, with an arylalkylhalogenide of the formulae ##STR39## wherein R3, R5, R6, R7, R8 and R9 are as before and Hal is a halogen atom, in the presence of a Lewis acid, for example titanium tetrachloride, aluminium chloride or zinc chloride. As solvent can be used for example methylene chloride or chloroform. The reaction is preferably carried out at room temperature stirring the starting materials for 6-12 hours.

The intermediates of formula (VI) and (VII) can be prepared for example as follows:

An aldehyde of the formula ##STR40## wherein R5, R6, R7 and n are as before, is reacted in alkaline or acidic conditions with a ketone, preferably acetone, to give a compound of the formula (VIII) via direct aldol condensation: ##STR41## wherein R8 is an alkyl as defined before, which compound in a second step is catalytically reduced to give the corresponding saturated compound of the formula: ##STR42## which compound in a third step is regioselectively brominated in methanol to give compounds of formula VII.

Another method for the preparation of the compounds of the general formula (VII) is the regioselective alkylation process of ketones in whih for example a halide compound of the formula (X) ##STR43## is reacted with a trimethylsilylenolether derivative of the general formula (XI) ##STR44## wherein R8 is an alkyl as before, in the presence of a Lewis acid, for example zinc (II) chloride, to give a compound of the formula (XII) ##STR45##

The compound of formula (XII) is further brominated as before to give compounds of the formula (VII).

When R8 and R2 are hydrogen yet another method for the preparation of compounds of the formula (VII) can be applied. In this method a halide of the general formula (XIII) ##STR46## is reacted with lithiated N,N-dimethylhydrazone of acetone followed by hydrolysis to give a compound of the general formula (XIV) ##STR47## which compounds are brominated as before to give compounds of the formula (VII).

According to another method for the preparation of compounds of the formula (VII), compounds of the formula (VIII) are selectively brominated using as brominating agent for example 2-carboxyethyltriphenylphosphonium perbromide, which has the formula (XV) ##STR48##

Yet another method for the preparation of compounds of the formula (VII) is possible via a directed aldol condensation, in which for example a compound of the formula (XVI) ##STR49## is reacted with the compound (XI) in the presence of a Lewis acid followed by dehydration to give a compound of the formula (XVII) ##STR50## which compound is further brominated as before to give a compound of the formula (VII).

When R11 is hydrogen, compounds of the formula (VII) can be prepared from compounds of the formula (XVI), wherein these are reacted with 1-lithiated N,N-dimethylhydrazone of methylalkylketone of the formula (XVIII) ##STR51##

Here in the first step compounds of the formula (XIX) are achieved, ##STR52## the bromination of which compounds are performed following the method above.

The preparation of compounds of the general formula (VII) can be accomplished from compounds of the general formula (XVII) by hydrogenation of the carbon-carbon bouble bond as well. The bromination in the second step leads to compounds of the formula (VII).

Alkylation of compounds of the general formula (XVII) when R2 and R10 are hydrogen can be accomplished, too. In this method a compound of the formula (XX) ##STR53## is reacted with an alkylation reagent such as dialkyllithiocuprate (XXI) which undergoes 1,4-conjugate addition

(R).sub.2 CuLi                                             (XXI)

to form compounds of the formula (XII).

Condensation of an arylalkylketone or its vinylogue with 4-imidazole aldehydes of the formula (XXII) ##STR54## provides further another method for the preparation of compounds according this invention. The condensation is performed for example in aqueous alcohol catalyzed by sodium hydroxide. Arylalkylketones or their vinylogues have the general formulae (XXIII) and (XXIV) ##STR55##

In the first step this condensation gives unsaturated ketones of the formulae (XXV) and (XXVI) ##STR56## which compounds are then hydrogenated to the end products according to the formulae (XXVII) and (XXVIII) ##STR57##

Yet another method for the preparation of compounds of formula (I) wherein R4 is H comprises reacting a compound of the formula ##STR58## wherein R1, R2, R5, R6 and R7 are as before and R is an alkyl of 1 to 4 carbon atoms with a Grignard reagent of the formula

R.sub.3 --CH.sub.2 MgHal

in a mixture of tetrahydrofuran and toluene with refluxing to give a compound of the formula ##STR59##

As stated herein above, the compounds of the general formula (I) and (II) and their non-toxic, pharmaceutically acceptable acid addition salts have valuable pharmacological properties and have been found to possess excellent antihypertensive properties.

Tests have shown that they also possess other pharmacological properties as well, for example, antithrombotic activity. Furthermore, antimycotic and antifungal properties have been found, too.

The processes described above for the preparation of compounds of formula (II) wherein X is ##STR60## result mainly in the trans isomer of the compound. The trans isomer can be converted to the cis isomer according to known methods, e.g. by heating it in the presence of an acid or by irradiating it with ultraviolet light.

Administration of isomeric compounds of formula (I) and (II), their non-toxic, pharmaceutically acceptable salts or mixtures thereof may be achieved parenterally, intravenously or orally. Typically, an effective amount of the derivative is combined with a suitable pharmaceutical carrier. As used herein, the term "effective amount" encompasses those amounts which yield the desired activity without causing adverse side-effects. The precise amount employed in a particular situation is dependent upon numerous factors such as method of administration, type of mammal, condition for which the derivative is administered, etc., and of course the structure of the derivative.

The pharmaceutical carriers which are typically employed with the derivatives of the present invention may be solid or liquid and are generally selected with the planned manner of administration in mind. Thus, for example, solid carriers include lactose, sucrose, gelatin and agar, while liquid carriers include water, syrup, peanut oil and olive oil. Other suitable carriers are well-known to those skilled in the art of pharmaceutical formulations. The combination of the derivative and the carrier may be fashioned into numerous acceptable forms, such as tablets, capsules, suppositories, solutions, emulsions, and powders.

The anti-hypertensive properties of the imidazole derivatives of the present invention have been determined by the following procedure. Sprague-Dawley rats of normal weight were first anesthetized with urethane. After this, the femoral artery was connected by way of a polyethylene tube with a blood pressure transducer. The test substance was then injected into the femoral vein or given intraperitoneally and the blood pressure and the pulse frequency were registered with a recorder.

In a further test for anti-hypertensive properties unanesthetized Wistar spontaneous hypertensive rats (SHR) were used. The test derivative was administered perorally by way of a tube into the stomach. The blood pressure was measured from the tail using an indirect bloodless method.

The diuretic activity was studied in rats by collecting the urine output during 0-5 hours after i.p. injection of the compounds. Before the test the animals were fasting overnight and got 10 ml water p.o. immediately before the injection.

The antithrombotic activity was investigated in vitro. The inhibiting activity of the compounds against ADP- and collagen-induced aggregation of thrombocytes was measured. In the test thrombocytes from a cow was used. To 1.2 ml of plasma containing 250000 thrombocytes/mm3 were added 50 μl of a solution of the compound to be tested. After 10 min incubation either ADP or collagen was added. The aggregation of the thrombocytes was turbidimetrically determined at λ=605 n m.

The antimicrobial activity was determined in vitro according to a qualitative test for antibacterial and antifungal activity, using the agar diffusion method, against the following standard organisms: Staphylococcus aureus, Streptococcus pyogenes, Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosus, Candida albicans and Aspergillus niger.

The antifungal activity was determined in vitro against the following fungi: Trichophyton rubrum, Trichophyton mentagrophytis, Microsporum canis, Epidermophyton floccosum, Chrysosporum, Candida albicans, Candida guilliermondi and Saccaromyces cerevisiae. The fungi were cultured by plating on an agar nutrient medium. The compound to be tested was added before the incubation. A measure of the efficiency of the compound tested is the radius of the circle, within which the growth of the fungi has been inhibited.

Acute toxicity was determined by using female mice of NMRI-Strain with an age of about 7 months and weighing 30-40 g. The administration of the test compound was i.v.

Thus the compound 4-[2-(2,6-dimethylphenyl)-1-methylethenyl]imidazole, which has a LD50 value of 40 mg/kg i.v. in mice, was found in the blood pressure study with anesthetized rats of normal weight described above to cause a registrable lowering of the blood pressure at a dose of 3 μg/kg i.e. At a dose of 10 μg/kg i.v. the blood pressure lowering was quite clear and at a dose of 100-300 μg/kg i.v. the reduction of the blood pressure was on an average 38%. The duration of the effect was at least 30 minutes (after which time the determination was interrupted). A blood pressure lowering of more than 40% was obtained when 2 mg/kg of the compound was administered perorally. The duration of the effect was at least 5 h.

The compound 4-[2-(2,6-dimethylphenyl)-1-methylethyl]imidazole (LD50 =40 mg/kg i.v. in mice) caused a blood pressure lowering of 20 percent measured 30 minutes after the administration at a dose of 100 μg/kg i.v. When 10 mg/kg of the compound was given perorally, a blood pressure drop of 25% was obtained. Duration was at least 5 h.

The compound 4-[(α-methyl)-2,6-dimethylbenzyl]imidazole (LD50 =150 mg/kg i.v. in mice) caused a blood pressure lowering of 30% at a dose of 1-10 mg/kg i.v. (30 min. after administration).

The compound 4-[(α-methyl)-2,3-dimethylbenzyl]imidazole (LD50 =40 mg/kg i.v. in mice) caused a blood pressure drop of 55% at 10 μg/kg i.v. (after 30 min.). Given perorally (1 mg/kg) the compound gave a blood pressure drop of 20%. The duration was at least 5 h.

The compound 4-[2-(2,6-dimethylphenyl)propyl]imidazole, which has a LD50 value of 200 mg/kg i.v. in mice gave a blood pressure drop of 30% at a dose of 3 mg/kg i.v., measured 30 min. after administration.

The compound 4-[2-(2,6-dimethylphenyl)-2-ethylethyl]imidazole gave a blood pressure drop of about 25% at a dose of 3 mg/kg i.v., measured 30 min. after administration.

The compound 4-[2-(2,6-dimethylphenyl)-1-ethylethenyl]-imidazole which has a LD50 value of 110 mg/kg i.v. in mice, gave a blood pressure drop of 35% at a dose of 3 mg/kg intraperitoneally measured 30 min. after administration.

The compound 4-(α-methyl-2-methylbenzyl)imidazole, which has a LD50 value of 100 mg/kg i.v. in mice, gave a blood pressure drop of 20% at a dose of 0.3 mg/kg intraperitoneally measured 30 min. after administration.

The compound 4-(α-methyl-2-chlorobenzyl)-imidazole, which has a LD50 value of 140 mg/kg i.v. in mice gave a blood pressure drop of about 20% at dose of 10 mg/kg i.v. 30 min. after administration.

The compound 4-[2-(2,6-dichlorophenyl)-1-methylethenyl]imidazole, which has a LD50 value of 50 mg/kg i.v. in mice gave a blood pressure drop of 25% at a dose of 0.3 mg/kg i.v. measured 30 min. after administration.

The compound 1-(4-imidazolyl)-1-(2,3-dimethylphenyl)ethylene, which has a LD50 value of 100 mg/kg i.v. in mice gave a blood pressure drop of about 40% at a dose of 3 mg/kg i.v. (after 30 min.) A blood pressure drop of 20% was obtained at a dose of 10 mg/kg perorally. The duration was at least 8 h.

The compound 4-(α-ethyl-2,3-dimethylbenzyl)-imidazole, which has a LD50 value of 40 mg/kg i.v. in mice gave a blood pressure drop of 40% at a dose of 1 mg/kg i.v. measured 30 min. after administration.

In the antithrombotic test, the compound 4-[2-(2,6-dimethylphenyl)-1-methylethenyl]imidazole inhibited the collagen-induced and the ADP-induced aggregation of thrombocytes completely.

In the diuretic test, the compound 4-[2-(2,6-dimethylphenyl)-1-methylethyl]-imidazole caused an urine output increase of 227% measured 3 h after administration. The dose was 1 mg/kg i.p.

In the same test, the compound, 4-[2-(3,4-methylenedioxyphenyl)propyl]imidazole, which has a LD50 value of 170 mg/kg i.v. in mice, caused an urine output increase of 275% at a dose of 1 mg/kg p.o. measured 3 hours after administration. The corresponding value for a dose of 5 mg/kg p.o. was 452%.

The clinical dosage ranges for the compounds of the invention for oral administration of the antihypertensives have been estimated as 0.05 to 1 mg/kg per day.

In the Examples below, where 1 H-NMR spectrum shifts are presented, the NMR spectra were determined with a Perkin-Elmer R 24 or a Bruker WP80DS apparatus using an external tetramethylsilane standard, from which the presented chemical shifts (δ, ppm) are tabulated. The letters s, d, t and m are used to indicate a singlet, doublet, triplet or multiplet, respectively and coupling constants in hertz when given. In the same connection, the number of hydrogen atoms is also stated. The compounds which are indicated as bases are tested in deuterium methanol, deuterium acetone or deuterium chloroform, while the values for compounds which are indicated as hydrochlorides were determined in deuterium oxide. The presented 13 C-NMR-spectrum were determined with a Bruker WP80DS apparatus.

The mass-spectra were determined with a Perkin-Elmer RMU-6E apparatus using direct inlet system. The temperature employed was the lowest temperature needed for the evaporation of the compound as base. In the examples the strongest and the most essential fragment-ions from a structural viewpoint are given as m/e values. In parenthesis is given the intensity of the fragment-ion in relation to the main peak.

EXAMPLE 1 4-[α,α-bis(2-methylphenyl)hydroxymethyl]-5-methylimidazole

4.9 g (0,2 mol) of dry magnesium turnings are covered with 50 ml of dry tetrahydrofuran. The mixture is heated to boiling and a solution of 34 g (0.2 mol) of 2-bromotoluene in 50 ml dry tetrahydrofuran is added dropwise at such a rate that smooth reaction is maintained. After the addition is complete, the reaction mixture is refluxed for about 30 minutes until the magnesium turnings are no longer react. The reaction mixture is then cooled to about 50° C. and 9,3 g of 5-methyl-4-imidazole carboxylic acid methyl ester are added in small portions. After the addition is complete, the mixture is refluxed for another 2 hours and the solvent is then distilled off to give about half of the original volume. The mixture is cooled and poured into 300 ml of cold water containing 15 ml of concentrated sulfuric acid, with agitation. The stirring is continued for an additional 15 minutes and the mixture is then filtered. The precipitate, filtered from the acidic water, which is the sulfate salt of the compound, is extracted to chloroform from basic water-ethanol solution. After evaporation, the crude product is recrystallized from acetone, m.p. 169°-171° C.

1 H-NMR (HCl-salt): 1.7 (s, 3H), 2.1 (s, 6H), 4.7 (s, 2H), 7.1 (m, 8H), 8.7 (s, 1H).

MS: 292 (55%), 274 (69%), 259 (100%), 232 (7%), 217 (9%), 201 (52%), 199 (72%), 167 (18%), 109 (63%).

EXAMPLE 2

4-[α,α-bis(2-methylphenyl)hydroxymethyl]imidazole

A Grignard reagent is prepared from 68,4 g of o-bromotoluene and 9,6 g of Mg-turnings in 200 ml of THF. To this solution 12,6 g of 4-imidazole carboxylic acid methylester are added at 50° C. and the reaction mixture is refluxed for 5 hours.

The mixture is then poured into cold water, which includes 60 ml of conc. HCl. The hydrochloride of the product is filtered off, washed with chloroform and recrystallized from isopropanol; yield 23 g (73%), m.p. 178°-179° C. Liberation of hydrochloride is achieved in water-ethanol with sodiumhydroxide; m.p. 138°-140° C.

1 H-NMR (HCl-salt): 1.9 (s, 6H), 4.6 (s, 3H), 6.7 (s, 1H), 7.0 (s, 8H), 8.7 (s, 1H).

EXAMPLE 3 4-(α,α-diphenyl)hydroxymethyl-5-methylimidazole

The compound is prepared by the method described in Example 2 except that bromobenzene is used in place of o-bromotoluene and 5-methyl-4-imidazole carboxylic acid methyl ester in place of 4-imidazolecarboxylic acid methyl ester; yield 18,5 g (70%), m.p. 188°-190° C. (as base from ethanol).

1 H-NMR: 1.4 (s, 3H), 4.7 (s, 2H), 7.0 (s, 10H), 7.2 (s, 1H).

MS: 264 (80%), 246 (78%), 231 (28%), 218 (20%), 204 (9%), 187 (100%), 109 (64%), 105 (26%), 77 (34%).

EXAMPLE 4 4-[[-α-(2-methylphenyl)]-2-methylbenzyl]imidazole

The starting material, 4-[α,α-bis(2-methylphenyl)hydroxymethyl]imidazole is dissolved in 100 ml of acetic acid. 100 mg of Pd/C are added and the reaction mixture is stirred vigorously in a hydrogen atmosphere at about 60° C. until the reaction is completed. The mixture is then filtered and distilled to a smaller volume. 70 ml of water are added and that mixture is then washed twice with 20 ml portions of chloroform. The aqueous phase is made alkaline with NaOH and extracted with chloroform (3×40 ml). The combined chloroform extracts are washed with water (1×10 ml) and dried over Na2 SO4. The solution is evaporated to dryness. Yield 93%, m.p. 228°-231° C. (from ethanol). Hydrochloride in ethyl acetate-isopropanol: m.p. 245°-254° C.

1 H-NMR: 2.1 (s, 6H), 4.7 (s, 2H), 5.8 (s, 1H), 6.6 (s, 1H), 6.9 (m, 8H), 8.7 (s, 1H)

EXAMPLE 5 4-(α-phenylbenzyl)-5-methylimidazole

The compound is prepared from 4-(α,α-diphenyl)hydroxymethyl-5-methylimidazole according to the method in Example 4. Yield 69%, m.p. 198°-204° C. (from ethanol).

1 H-NMR: 1.6 (s, 3H), 4.5 (s, 1H), 5.3 (s, 1H), 6.8 (s, 10H), 7.3 (s, 1H).

EXAMPLE 6 4-[α-(2-methylphenyl)-α-(2-methylbenzyl)]-5-methylimidazole

The compound is prepared according to the method in Example 4 using 4-[α,α-bis-(2-methylphenyl)hydroxymethyl]-5-methylimidazole as starting material. Yield 79%, m.p. 178°-180° C. (from water-ethanol).

1 H NMR: 1.4 (s, 3H), 1.8 (s, 6H), 4.6 (s, 1H), 5.35 (s, 1H), 7.1 (m, 8H), 7.15 (s, 1H).

EXAMPLE 7 4-[[α-(2,3-dimethylphenyl)-α-methyl]hydroxymethyl]imidazole, 1-(4-imidazolyl)-1-(2,3-dimethylphenyl)ethylene and 4-(α-methyl-2,3-dimethylbenzyl)imidazole

For the preparation of 2,3-dimethylmagnesiumbromide in the first step, 4,9 g of dry magnesium turnings are covered with 50 ml of dry tetrahydrofuran.

The mixture is heated to boiling and a solution of 37 g of 2,3-dimethylbromobenzene in 50 ml dry of tetrahydrofuran is added dropwise at such a rate that a smooth reaction is maintained. After the addition is complete the reaction mixture is refluxed for about 30 minutes until the magnesium turnings no longer react.

In the same way in another flask of methylmagnesiumbromide is prepared from 2.4 g of magnesium turnings and 9.5 g of methylbromide in tetrahydrofuran.

Yet another flask of 12,6 g of 4-imidazolecarboxylic acid methylester, is added to 100 ml of dry tetrahydrofuran and the mixture is stirred while heating to about 50° C. To this is then dropped the earlier prepared 2,3-dimethylmagnesiumbromide solution and immediately after that the methylmagnesiumbromide solution. To complete the reaction, the mixture is refluxed for several hours. The solvent is then distilled off to give about half of the original volume. The mixture is cooled and poured into 350 ml of cold water containing 50 ml of concentrated sulfuric acid, with agitation. The stirring is continued for an additional 15 minutes and the mixture is then filtered.

The pH of the filtrate is adjusted slightly basic and the mixture is extracted three times with 50 ml portions of methylene chloride. The combined methylene chloride extracts are washed with water and evaporated to dryness. The residue which contains crude 4-[[α-(2,3-dimethylphenyl)α-methyl]hydroxymethyl]imidazole is further purified column chromatographically in silicagel using chloroform methanol as eluent. 1-(4-imidazolyl)-1-(2,3-dimethylphenyl)-ethylene is then obtained from the above product by heating it with potassiumhydrogen sulphate at 136° C.

1 H-NMR (HCl-salt): 2.104 (s, 3H), 2.313 (s, 3H), 5.187 (s, 2H), 5.358 (s, 1H), 6.106 (s, 1H), 7.03-7.22 (m, 4H), 8.98 (s, 1H).

13 C-NMR (HCl-salt): Signals at ppm: 18.073, 21.857, 118.789, 119.455, 127.961, 129.475, 132.230, 135.802, 136.498, 136.892, 137.921, 139.949, 140.070.

Melting point as base: 137°-140° C.

4-(α-methyl-2,3-dimethylbenzyl)imidazole is obtained via hydrogenation with palladium-on-carbon catalyst in 2-N HCl according to the method desribed before.

1 H-NMR (HCl-salt): 1.708 (d, 3H), 2.370 (broad s, 3H), 4.688 (q, 1H), 4.933 (s, 2H), 7.079-7.263 (m, 3H), 7.361 (s, 1H), 8.780 (s, 1H).

13 C-NMR (HCl-salt): Signals at ppm: 16.529, 21.917, 22.462, 34.662, 117.881, 126.660, 128.385, 131.079, 135.650, 136.952, 140.161, 140.163, 142.855.

By the same method for example the following compounds were prepared:

4-(α-methyl-2,6-dimethylbenzyl)imidazole, M.p. (oxalate): 98°-99° C.

4-(α-ethyl-2,3-dimethylbenzyl)imidazole, M.p. (HCl-salt): 175°-177° C.

4-(α-butyl-2-methylbenzyl)imidazole.

4-(α-methyl-2,3-dimethylbenzyl)-2-methylimidazole.

EXAMPLE 8 4-(2,6-dimethylphenyl)-3-buten-2-one

13.4 g (0,1 mol) of 2,6-dimethylbenzaldehyde, 100 ml of acetone, 100 ml of water and 2 g of calcium hydroxide are mixed together and refluxed for about 20-25 h with agitation. The precipitate is filtered off from the cold reaction mixture. 1 l of ice water is added to the filtrate with agitation. The product is crystallized at a yield of about 90%. M.p. of the recrystallized product: 34°-35° C.

1 H-NMR: 7.55 (1Hd, 16.5), 7.00 (3Hs), 6.26 (1Hd, 16.5), 2.37 (3Hs), 2.31 (6Hs).

EXAMPLE 9 4-(2,6-dimethylphenyl)-2-pentanone

To a mixture containing 20 g of CuI and 50 ml of tetrahydrofuran (THF) are added 105 ml of methyllithium dropwise during with agitation in a nitrogen atmosphere at a temperature of 0° C. or lower until the yellow precipitate barely dissolves. Then 8,7 g of 4-(2,6-dimethylphenyl)-3-buten-2-one in 50 ml of THF are added slowly at 0° C. The stirring is continued for an additional 2 h with a gradual increase of the temperature to +25° C. The reaction mixture obtained is hydrolysed with 300 ml of a solution of NH4 Cl. The ether layer is removed, dried and evaporated to give the crude product.

1 H-NMR: 6.85 (3Hs), 3.78 (1Hq+t, 7.5), 2.76 (2Hd, 7.5), 2.34 (6Hs), 1.99 (3Hs), 1.27 (3Hd, 7.5).

According to the same method, the compound 4-phenyl-2-pentanone was prepared.

1 H-NMR: 7.10 (5Hs), 3.26 (1Hq+t, 7.5), 2.62 (2Hd, fine structur), 1.94 (3Hs, 1.20 (3Hd, 7).

Similarly 4-(3,4-dimethylenedioxyphenyl)-2-pentanone.

1 H-NMR: 6.62 (3H, s), 5.83 (2H, s), 3.20 (1Hq+t, 7), 2.67 (2H, d7), 2.04 (3Hs), 1.26 (3Hd7).

EXAMPLE 10 1-bromo-4-(2,6-dimethylphenyl)-2-pentanone

To 3,8 g of 4-(2,6-dimethylphenyl)-2-pentanone in 25 ml of dry methanol 1.04 ml of bromine are added dropwise rapidly at a temperature not higher than +5° C. Stirring is continued until the bromine colour disappears, while the temperature slowly rises to +20° C. After evaporation the product is obtained at a yield of at least 70%.

1 H-NMR: 6.98 (3Hs), 3.80 (1Hm), 3.67 (2Hs), 3.02 (2Hd), 2.35 (6Hs), 1.33 (3Hd, 7).

According to the same method the compounds 1-bromo-4-phenyl-2-pentanone and 1-bromo-4-(2,6-dimethylphenyl)-3-methyl-2-butanone were prepared.

Similarly using two equivalents of bromine:

1-bromo-4-(2-bromo-4,5-methylenedioxyphenyl)-2-pentanone.

1 H-NMR: 6.9 (1H, s), 6.67 (1H, s), 5.87 (2Hs), 3.80 (2Hs), 2.9 (3Hm), 1.19 (3Hd7).

EXAMPLE 11 4-[2(2,6-dimethylphenyl)propyl]imidazole

5.4 g of 1-bromo-4-(2,6-dimethylphenyl)-2-pentanone, 50 ml of formamide and 5 ml of water are refluxed with stirring for 3 h. The mixture is poured into 300 ml of water (pH 4-5), washed with ether, neutralized with NaHCO3 and extracted with methylene chloride. After drying and evaporation 2.5 g of product are obtained. This is dissolved in ethyl acetate and HCl/ethylacetate is added. The product is evaporated to dryness, washed with ether, dissolved in water, neutralized with NaHCO3 and extracted with methylene chloride. The evaporation residue is dissolved in ethyl acetate and the final product is precipitated as oxalate or hydrochloride. M.p. of the hydrochloride 194°-198° C.

1 H-NMR (HCl-salt): 8.70 (1Hs), 6.9 (4Hs), 3.65 (1Hm), 3.21 (2H,d 8), 2.39 (6H broad s), 1.45 (3Hd 7).

According to the same method, the following compounds were prepared: 4-[2-(2,6-dimethylphenyl)-1-methylethyl]imidazole. M.p. of the oxalate 161°-5° C.

1 H-NMR (oxalate): 8.75 (1H broad s), 7.05 (1Hs), 7.00 (3Hs), 3.0 (3Hm), 2.20 (6Hs), 1.31 (3Hd).

4-(2-phenylpropyl)imidazole (as oxalate)

1 H-NMR: 8.52 (1Hs), 7.22 (5Hs), 6.97 (1Hs), 3.05 (3Hm), 1.35 (3Hd) M.p. of the oxalate: 166°-168° C.

4-[2-(3,4-methylenedioxyphenyl)propyl]imidazole

1 H-NMR (as oxalate): 8.70 (1H, s), 7.11 (1H, s), 6.78 (3H, m), 5.95 (2H, s), 3.08 (3H, m), 1.40 (3H, d).

M.p. of oxalate: 154°-156° C.

4-[2-(2,6-dimethylphenyl)butyl]imidazole

M.p. of oxalate 176°-9° C.

1 H-NMR: 8.25 (1H, broad s), 6.95 (3H, s), 6.68 (1H, s), 3.2 (3H, m), 2.45 (3H, s), 2.6-2.0 (2H, m), 2.06 (3H, s), 1.87 (3H, t)

4-[2-(2-bromo-4,5-methylenedioxyphenyl)propyl]imidazole

4-[2-(2,3-dimethylphenyl)propyl]imidazole, M.p. (base): 109°-120° C.

1 H-NMR: 1.25 (d, 3H), 2.17 (s, 3H), 2.24 (s, 3H), 3.0 (d, 2H), 3.5 (m, 1H), 5.26 (s, H2 O), 7.0 (m, 3H), 8.09 (s, 1H), 8.65 (s, 1H).

EXAMPLE 12 4-(2,6-dimethylphenyl)-3-methyl-3-buten-2-one

A mixture of 13.4 g of 2,6-dimethylbenzaldehyde and 15 ml of 2-butanone is saturated with gaseous HCl with stirring. The starting temperature is 0° C., and it is raised to 20°-25° C. in 2 h. The reaction mixture is poured into 0,5 l of cold water, extracted with toluene and washed with a NaHCO3 -solution. The dried toluene extract is filtered, toluene and free 2-butanone are distilled off. The product is obtained by crystallization from di-isopropylether. M.p. 43°-44° C.

1 H-NMR: 7.38 (1Hs), 6.98 (3Hs), 2.42 (3Hs), 2.11 (6Hs), 1.59 (3Hd, 1.4).

EXAMPLE 13 1-bromo-4-(2,6-dimethylphenyl)-3-methyl-3-buten-2-one

To a mixture of 3,8 g of 4-(2,6-dimethylphenyl)-3-methyl-3-buten-2-one in 50 ml of THF a solution of 13 g of 2-carboxyethyltriphenylphosphoniumperbromide in 50 ml of THF is added dropwise at room temperature.

Stirring is continued for another 2 h. 200 ml of water and 100 ml of ligroin are added. The organic layer is washed with a Na2 CO3 -solution and water. After filtration and evaporation 5,5 g of crude product containing 85-90% of 1-bromo-4-(2,6-dimethylphenyl)-3-methyl-3-buten-2-one are obtained.

1 H-NMR: 7.51 (1H broad s), 7.05 (3Hs), 4.27 (2Hs), 2.18 (6Hs), 1.68 (3Hd, 1.3)

EXAMPLE 14 4-[2-(2,6-dimethylphenyl)-1-methylethenyl]imidazole E-isomer

The compound is prepared according to the method described in Example 12, except that 1-bromo-4-(2,6-dimethylphenyl)-3-methyl-3-buten-2-one is used instead of 1-bromo-4-(2,6-dimethylphenyl)-2-pentanone. M.p. of the hydrochloride 260°-262° C.

1 H-NMR: 8.82 (1H, d), 7.36 (1H, d), 7.20 (1H, broad s), 7.08 (3Hs), 2.20 (6Hs), 1.82 (3H,d,1.2).

Using the same method the following compounds were prepared:

4-[2-(2,6-dichlorophenyl)-1-methylethenyl]imidazole. M.p. of the hydrochloride 210°-212° C.

1 H-NMR (HCl-salt): 1.9 (s, 3H), 4.6 (broad signal, H2 O), 6.85 (s, 1H), 7.0-7.4 (m, 1+3H), 7.6 (s, 1H).

4-[2-(2,6-dimethylphenyl)-1-ethylethenyl]imidazole. M.p. of the hydrochloride 257°-258° C.

1 H-NMR (HCl-salt): 1.1 (t, 3H), 2.35 (s, 6H), 2.4 (q, 2H), 4.8 (broad signal, H2 O), 7.1 (2×s, 3+1H), 7.65 (s, 1H), 8.95 (s, 1H).

4-[2-(2,6-dimethylphenyl)-1-methylethenyl]-5-methylimidazole. M.p. of the hydrochloride 250°-252° C.

EXAMPLE 15 4-(α-methyl-2,6-dimethylbenzyl)imidazole

To a mixture of N-(trimethylsilyl)imidazole (1.4 g) and titanium tetrachloride (1.6 ml) in dry chloroform (20 ml) a solution of 1-chloro-1-(2,6-dimethylphenyl)ethane (1.7 g) in dry chloroform (10 ml) was added. After stirring for 5 h at room temperature the product mixture was poured onto water, washed with ether and neutralized with sodium hydrogen carbonate. Filtration and extraction with methylene chloride gave 4-[(α-methyl)-2,6-dimethylbenzyl]imidazole, yield 33%.

1 H-NMR: δCDCl3 11.4 (1H, broad), 7.19 (1H, s), 6.83 (3H, s), 6.56 (1H, s), 4.52 (2H,q 6), 2.11 (6H, s), 1.63 (3H,d 6).

M.p. of the hydrochloride: 208°-10° C.

13 C-NMR (as hydrochloride): δCD3 OD 139.8 (1C, s), 139.1 (1C, s), 137.6 (2C, s), 134.9 (1C, d), 130.8 (2C, d), 128.4 (1C, d), 116.6 (1C, d), 32.8 (1C, d), 20.6 (2C, q), 17.0 (1C, q).

Using the same method the following compounds were prepared:

4-(α-methyl-2-methylbenzyl)imidazole. M.p. of the hydrochloride 156°-160° C.

1 H-NMR (HCl-salt): 1.63 (d, 3H), 2.40 (s, 3H), 4.52 (q, 1H), 5.10 (s, H2 O), 6.9-7.2 (m, 3H), 7.36 (s, 1H), 8.83 (d, 1H).

4-(α-methyl-2,3-dimethylbenzyl)imidazol

13 C-NMR (HCl-salt): 16.529, 21.917, 22.462, 34.662, 117.881, 126.660, 128.385, 131.079, 135.650, 136.952, 140.161, 140.161, 142.855.

4-(α-methyl-2-chlorobenzyl)imidazole. M.p. of the oxalate 214°-216° C.

EXAMPLE 16 4-(α-ethyl-2,3-dimethylbenzyl)imidazole

6.0 g of 4-[α-(2,3-dimethylphenyl)ethoxymethyl]-imidazole is dissolved in toluene. To this solution is then added 22.8 g of ethylmagnesiumbromide in tetrahydrofuran and the mixture is refluxed for 20 hours. The mixture is then poured into cold hydrochloric acid and most of the organic solvents is evaporated. The mixture is extracted with methylene chloride. The extract is washed with water, dilute sodium hydroxide solution and water and evaporated to dryness.

The residue, which is crude product is further purified by liquid chromatography by using a column of silica gel and chloroform-methanol as eluent. After liquid chromatographic purification the product melts at 173°-176° C. as hydrochloride.

Claims (12)

We claim:
1. A substituted imidazole of the formula: ##STR61## or a non-toxic pharmaceutically acceptable addition salt thereof, wherein R1 is H, alkyl of 1 to 4 carbon atoms or --CH2 OH; R2 is H or --CH3 ; R3 is --CH3, --CH2 CH3, --CH2 CH2 CH3, ##STR62## --CH2 CH2 CH2 CH3, or --CH2 CH═CH2, and R4 is H or OH; or R3 and R4 together represent ═CH2, ═CH--CH3, ═CH--CH2 --CH3, ##STR63## or ═CH--CH2 CH2 CH2 CH3 ; R5 R6 and R7 which can be the same or different are H, --CH3, --CH2 CH3, halogen, OH or --OCH3, at least one of R5, R6 and R7 being other than hydrogen, or R5 is hydrogen and R6 and R7 together form an --O--CH2 --O--bridge between two adjacent carbon atoms in the phenyl group.
2. A compound of formula (I) according to claim 1 wherein each of R5, R6 and R7, which can be the same or different, is hydrogen, methyl, ethyl or halogen, at least one of R5, R6 and R7 being other than hydrogen.
3. A compound of formula (I) according to claim 1, wherein R4 is hydrogen and R3 is methyl, ethyl, propyl, isopropyl or butyl.
4. A compound of formula (I) according to claim 3 wherein R1 is methyl.
5. A compound according to claim 1 which is 4-[(α-methyl)-2,6-dimethylbenzyl]imidazole or a non-toxic pharmaceutically acceptable acid addition salt thereof.
6. A cmpound according to claim 1 which is 4-[(α-methyl)-2,3-dimethylbenzyl]imidazole or a non-toxic pharmaceutically acceptable acid addition salt thereof.
7. A compound according to claim 1 which is 4-[(α-methyl)-2-methylbenzyl]imidazole or a non-toxic pharmaceutically acceptable acid addition salt thereof.
8. A compound according to claim 1 which is 4-[(α-methyl)-2-chlorobenzyl]imidazole or a non-toxic pharmaceutically acceptable acid addition salt thereof.
9. A compound according to claim 1 which is 4-[(α-ethyl)-2,3-dimethylbenzyl]imidazole or a non-toxic pharmaceutically acceptable acid addition salt thereof.
10. A compound according to claim 1 which is 1-(4-imidazolyl)-1-(2,3-dimethylphenyl)-ethylene or a non-toxic pharmaceutically acceptable acid addition salt thereof.
11. A pharmaceutical composition useful for producing an anti-hypertensive effect comprising an effective amount of a substituted imidazole of the formula: ##STR64## or a non-toxic pharmaceutically acceptable acid addition salt thereof, wherein R1 is H, alkyl of 1 to 4 carbon atoms or --CH2 OH; R2 is H or --CH3 ; R3 is --CH3, --CH2 CH3, --CH2 CH2 CH3, ##STR65## --CH2 CH2 CH2 CH3, or --CH2 CH═CH2, and R4 is H or OH; or R3 and R4 together represent ═CH2, ═CH--CH3, ═CH--CH2 --CH3, ##STR66## or ═CH--CH2 CH2 CH2 CH3 ; R5 R6 and R7 which can be the same or different are H, --CH3, --CH2 CH3, halogen, OH or --OCH3, at least one of R5, R6 and R7 being other than hydrogen, or R5 is hydrogen and R6 and R7 together form an --O--CH2 --O--bridge between two adjacent carbon atoms in the phenyl group, and a compatible, pharmaceutically acceptable carrier therefor.
12. A method of producing an anti-hypertensive effect in a subject in whom such an effect is desired which comprises administering thereto an amount effective as an antihypertensive agent of a substituted imidazole as defined in claim 1 or of a non-toxic pharmaceutically acceptable acid addition salt thereof.
US06396000 1981-07-10 1982-07-07 Antihypertensive substituted imidazole derivatives Expired - Lifetime US4544664A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB8121333 1981-07-10
GB8121333A GB2101114B (en) 1981-07-10 1981-07-10 Substituted imidazole derivatives and their preparation and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US06713654 Division US4639464A (en) 1981-07-10 1985-03-19 Antihypertensive substituted imidazole derivatives

Publications (1)

Publication Number Publication Date
US4544664A true US4544664A (en) 1985-10-01

Family

ID=10523160

Family Applications (3)

Application Number Title Priority Date Filing Date
US06396000 Expired - Lifetime US4544664A (en) 1981-07-10 1982-07-07 Antihypertensive substituted imidazole derivatives
US06713654 Expired - Lifetime US4639464A (en) 1981-07-10 1985-03-19 Antihypertensive substituted imidazole derivatives
US07141810 Expired - Lifetime US4826864A (en) 1981-07-10 1988-01-11 Substituted imidazole derivatives useful as antihypertensive or antithromtic agent or divretic

Family Applications After (2)

Application Number Title Priority Date Filing Date
US06713654 Expired - Lifetime US4639464A (en) 1981-07-10 1985-03-19 Antihypertensive substituted imidazole derivatives
US07141810 Expired - Lifetime US4826864A (en) 1981-07-10 1988-01-11 Substituted imidazole derivatives useful as antihypertensive or antithromtic agent or divretic

Country Status (9)

Country Link
US (3) US4544664A (en)
EP (1) EP0072615B1 (en)
JP (1) JPH0372621B2 (en)
KR (1) KR860001864B1 (en)
CA (1) CA1184559A (en)
DE (1) DE3268111D1 (en)
DK (2) DK158307C (en)
FI (1) FI77858C (en)
GB (1) GB2101114B (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639464A (en) * 1981-07-10 1987-01-27 Farmos Group, Ltd. Antihypertensive substituted imidazole derivatives
US4661508A (en) * 1984-06-18 1987-04-28 Eli Lilly And Company Aromatase inhibiting α,α-diphenyl-4(5)imidazole-methanes or -ethanes
US4670455A (en) * 1984-12-04 1987-06-02 Farmos-Yhtyma Oy Method of bringing about sedation and/or analgesia in a mammal
US4684659A (en) * 1980-02-13 1987-08-04 Farmos-Yhtyma Oy Antimypertensive substituted imidazoles
US4910214A (en) * 1987-07-16 1990-03-20 Farmos Yhtyma Oy Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist
US5439928A (en) * 1989-03-30 1995-08-08 Orion-Yhtyma Oy Aromatase inhibiting 4(5)-imidazoles
US5747515A (en) * 1993-07-06 1998-05-05 Astra Aktiebolag Heterocyclic compounds and compositions having nevropharmacological potential
WO2002065941A2 (en) * 2001-02-15 2002-08-29 Radiant Medical, Inc. Method of controlling body temperature
US6448263B1 (en) 1997-06-25 2002-09-10 Pfizer Inc. Treatment of insulin resistance with growth hormone secretagogues
US6518257B1 (en) * 1999-10-22 2003-02-11 Takeda Chemical Industries, Ltd. 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof
US6572638B1 (en) 1999-08-11 2003-06-03 Radiant Medical, Inc. Method of controlling body temperature while inhibiting thermoregulatory responses
EP1918282A1 (en) * 2006-11-06 2008-05-07 "Joint Stock Company Grindeks" Method for preparing medetomidine and its salts
US20100010006A1 (en) * 2008-07-08 2010-01-14 Lance William R Pharmaceutical Combination for and Method of Anesthetizing and Immobilizing Non-Domesticated Mammals
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US9045433B2 (en) 2012-05-08 2015-06-02 Lonza Ltd. Method for preparation of medetomidine
CN101805294B (en) * 2010-01-12 2015-06-10 北京华禧联合科技发展有限公司 Preparation of dexmedetomidine hydrochloride key intermediate
US9126915B2 (en) 2012-05-08 2015-09-08 Lonza Ltd. Method for preparation of 2-(2,3-dimethylphenyl)-1-propanal
US9126914B1 (en) 2012-06-28 2015-09-08 Lonza Ltd. Method for preparation of 2-(2,3-dimethylphenyl)-1-propanal with chloroacetone
US9156793B2 (en) 2012-06-28 2015-10-13 Lonza Ltd. Method for preparation of medetomidine with chloroacetone
US9616049B2 (en) 2012-01-04 2017-04-11 Hospira, Inc. Dexmedetomidine premix formulation
US9649296B1 (en) 2016-04-20 2017-05-16 Slypharma, Llc. Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4482723A (en) * 1983-04-11 1984-11-13 Pfizer Inc. Process for preparation of 4-acetyl-2-substituted-imidazoles
US4605661A (en) * 1984-06-18 1986-08-12 Eli Lilly And Company Aromastase inhibiting α,α-diarylimidazole-4(5)-propionitriles, α,α-diarylimidazole-4(5)-propionamides, and 4(5)-(2,2-diarylethyl)imidazoles
CA1238640A (en) * 1984-06-18 1988-06-28 Kenneth S. Hirsch 4(5)-substituted imidazoles
US4600683A (en) * 1985-04-22 1986-07-15 International Business Machines Corp. Cross-linked polyalkenyl phenol based photoresist compositions
GB8626287D0 (en) * 1986-11-04 1986-12-03 Ucb Sa Substituted 1h-imidazoles
GB2210875B (en) * 1987-10-09 1991-05-29 Farmos Oy Aromatase inhibiting 4(5)-imidazoles
GB2215206B (en) * 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
GB8810067D0 (en) * 1988-04-28 1988-06-02 Ucb Sa Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides
GB2229719B (en) * 1989-03-30 1992-04-29 Farmos Oy Novel aromatase inhibiting 4(5)-imidazoles
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5151526A (en) * 1990-10-11 1992-09-29 The United States Of America As Represented By The Secretary Of The Army 4-[1-(1-naphthalenyl)ethyl]-1H-imidazole, method of making and use as an anesthetic
DE4033042C2 (en) * 1990-10-18 1993-05-13 Joseph, Heinz W., Dr., 7150 Backnang, De
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB2256135B (en) * 1991-05-31 1995-01-18 Orion Yhtymae Oy Transdermal administration of 4-substituted imidazoles
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
GB9521680D0 (en) * 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
JP4610480B2 (en) 2003-03-07 2011-01-12 アステラス製薬株式会社 Nitrogen-containing heterocyclic derivative having 2,6-disubstituted styryl
WO2007085556A3 (en) * 2006-01-27 2007-10-04 Guido Galley Use of 4-imidazole derivatives for cns disorders
US20080146523A1 (en) * 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
US8124774B2 (en) 2007-05-23 2012-02-28 Allergan, Inc. Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
US8198315B2 (en) 2007-05-23 2012-06-12 Allergan, Inc. Therapeutic substituted cyclic lactams
GB2453982B (en) * 2007-10-24 2009-09-16 Norbrook Lab Ltd Chemical process for the preparation of Medetomidine
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
CA2712256A1 (en) * 2008-01-18 2009-07-23 Allergan, Inc. Substitued-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors
CN101921234B (en) 2009-06-12 2012-05-30 中化宁波(集团)有限公司 Method for preparing dexmedetomidine
CN102753532B (en) 2009-12-09 2015-05-13 I-技术有限公司 Process for preparation of medetomidine
RU2448094C1 (en) * 2010-12-09 2012-04-20 Олег Геннадьевич Еремин Improved method of producing medetomidine or non-toxic pharmaceutically acceptable salts thereof
RU2448095C1 (en) * 2010-12-09 2012-04-20 Олег Геннадьевич Еремин Method of producing detomidine or non-toxic pharmaceutically acceptable salts thereof
WO2013014428A1 (en) 2011-07-22 2013-01-31 Cambrex Karlskoga Ab New processes for preparing 4-substituted imidazoles
WO2013069025A1 (en) 2011-11-11 2013-05-16 Neon Laboratories Ltd. "process for the preparation of dexmedetomidine"
WO2012172119A3 (en) * 2012-05-08 2013-04-04 Lonza Ltd Method for the preparation of medetomidine
CN104447562A (en) * 2014-03-27 2015-03-25 宁波天衡药业股份有限公司 New method for preparing dexmedetomidine hydrochloride key intermediate
WO2016177884A1 (en) 2015-05-06 2016-11-10 I-Tech Ab Medetomidine for use in controlling parasitic crustaceans on fish

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2946804A (en) * 1958-12-29 1960-07-26 Abbott Lab (5-methyl-4-imidazolyl)-diphenyl carbinol salts and lower alkyl quaternaries
EP0024829A1 (en) * 1979-08-07 1981-03-11 Farmos-Yhtyma Oy 4-Benzyl- and 4-benzoylimidazole derivatives, processes for their preparation and pharmaceutical compositions comprising the same
EP0034474A1 (en) * 1980-02-13 1981-08-26 Farmos-Yhtyma Oy Substituted imidazoles, their preparation and pharmaceutical compositions containing the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE793407A (en) * 1971-12-28 1973-06-28 Hoechst Ag Imidazolyl - (2) carbinols having a hypolipidemic activity and their method of preparing
GB2092569B (en) * 1981-02-05 1984-09-19 Farmos Oy Substituted imidazole derivatives and their preparation and use
GB2101114B (en) * 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2946804A (en) * 1958-12-29 1960-07-26 Abbott Lab (5-methyl-4-imidazolyl)-diphenyl carbinol salts and lower alkyl quaternaries
EP0024829A1 (en) * 1979-08-07 1981-03-11 Farmos-Yhtyma Oy 4-Benzyl- and 4-benzoylimidazole derivatives, processes for their preparation and pharmaceutical compositions comprising the same
US4443466A (en) * 1979-08-07 1984-04-17 Farmos-Yhtyma OY (Farmos Group Ltd.) 4-Benzyl- and 4-benzoyl-substituted imidazole derivatives and use as medicaments
EP0034474A1 (en) * 1980-02-13 1981-08-26 Farmos-Yhtyma Oy Substituted imidazoles, their preparation and pharmaceutical compositions containing the same
EP0034473A2 (en) * 1980-02-13 1981-08-26 Farmos-Yhtyma Oy Substituted imidazoles, their preparation and pharmaceutical compositions containing the same
US4333947A (en) * 1980-02-13 1982-06-08 Farmos-Yhtyma Oy Substituted imidazoles and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Kelley, J., et al., J. Pharm. Sci. , 70(3), 341 343, (1981). *
Kelley, J., et al., J. Pharm. Sci., 70(3), 341-343, (1981).

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684659A (en) * 1980-02-13 1987-08-04 Farmos-Yhtyma Oy Antimypertensive substituted imidazoles
US4639464A (en) * 1981-07-10 1987-01-27 Farmos Group, Ltd. Antihypertensive substituted imidazole derivatives
US4661508A (en) * 1984-06-18 1987-04-28 Eli Lilly And Company Aromatase inhibiting α,α-diphenyl-4(5)imidazole-methanes or -ethanes
US4670455A (en) * 1984-12-04 1987-06-02 Farmos-Yhtyma Oy Method of bringing about sedation and/or analgesia in a mammal
US4910214A (en) * 1987-07-16 1990-03-20 Farmos Yhtyma Oy Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist
US5439928A (en) * 1989-03-30 1995-08-08 Orion-Yhtyma Oy Aromatase inhibiting 4(5)-imidazoles
US5747515A (en) * 1993-07-06 1998-05-05 Astra Aktiebolag Heterocyclic compounds and compositions having nevropharmacological potential
US6630487B2 (en) 1997-06-25 2003-10-07 Pfizer Inc. Treatment of insulin resistance with growth hormone secretagogues
US6448263B1 (en) 1997-06-25 2002-09-10 Pfizer Inc. Treatment of insulin resistance with growth hormone secretagogues
US6867202B1 (en) 1997-06-25 2005-03-15 Pfizer Inc. Treatment of insulin resistance
US20040073280A1 (en) * 1999-08-11 2004-04-15 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
US6572638B1 (en) 1999-08-11 2003-06-03 Radiant Medical, Inc. Method of controlling body temperature while inhibiting thermoregulatory responses
US6702839B1 (en) 1999-08-11 2004-03-09 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
US7008444B2 (en) 1999-08-11 2006-03-07 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
US6518257B1 (en) * 1999-10-22 2003-02-11 Takeda Chemical Industries, Ltd. 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof
US6582457B2 (en) * 2001-02-15 2003-06-24 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
WO2002065941A3 (en) * 2001-02-15 2003-04-17 Radiant Medical Inc Method of controlling body temperature
WO2002065941A2 (en) * 2001-02-15 2002-08-29 Radiant Medical, Inc. Method of controlling body temperature
EP1918282A1 (en) * 2006-11-06 2008-05-07 "Joint Stock Company Grindeks" Method for preparing medetomidine and its salts
WO2008055852A1 (en) 2006-11-06 2008-05-15 Grindeks, A Joint Stock Company Method for preparing medetomidine and its salts
US7902377B2 (en) 2006-11-06 2011-03-08 Jsc Grindeks Method for preparing medetomidine and its salts
US20100048915A1 (en) * 2006-11-06 2010-02-25 Grindeks A Joint Stock Company Method for preparing medetomidine and its salts.
CN101535272B (en) 2006-11-06 2011-10-05 格林代克斯联合股份公司 Method for preparing medetomidine and its salts
US7795263B2 (en) 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
US20100010006A1 (en) * 2008-07-08 2010-01-14 Lance William R Pharmaceutical Combination for and Method of Anesthetizing and Immobilizing Non-Domesticated Mammals
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US9161912B2 (en) 2008-12-23 2015-10-20 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
CN101805294B (en) * 2010-01-12 2015-06-10 北京华禧联合科技发展有限公司 Preparation of dexmedetomidine hydrochloride key intermediate
US9616049B2 (en) 2012-01-04 2017-04-11 Hospira, Inc. Dexmedetomidine premix formulation
US9045433B2 (en) 2012-05-08 2015-06-02 Lonza Ltd. Method for preparation of medetomidine
US9126915B2 (en) 2012-05-08 2015-09-08 Lonza Ltd. Method for preparation of 2-(2,3-dimethylphenyl)-1-propanal
US9126914B1 (en) 2012-06-28 2015-09-08 Lonza Ltd. Method for preparation of 2-(2,3-dimethylphenyl)-1-propanal with chloroacetone
US9156793B2 (en) 2012-06-28 2015-10-13 Lonza Ltd. Method for preparation of medetomidine with chloroacetone
US9434694B2 (en) 2012-06-28 2016-09-06 Lonza Ltd. Method for preparation of medetomidine with chloroacetone
US9649296B1 (en) 2016-04-20 2017-05-16 Slypharma, Llc. Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container

Also Published As

Publication number Publication date Type
FI77858B (en) 1989-01-31 application
DE3268111D1 (en) 1986-02-06 grant
EP0072615A1 (en) 1983-02-23 application
JPH0372621B2 (en) 1991-11-19 grant
GB2101114B (en) 1985-05-22 grant
KR840000507A (en) 1984-02-22 application
JPS5818365A (en) 1983-02-02 application
FI822140A (en) application
FI822140L (en) 1983-01-11 grant
DK158307B (en) 1990-04-30 grant
DK304382A (en) 1983-01-11 application
GB2101114A (en) 1983-01-12 application
DK630486D0 (en) 1986-12-29 grant
JP1707964C (en) grant
DK630486A (en) 1986-12-29 application
KR860001864B1 (en) 1986-10-24 grant
DK160610C (en) 1991-09-02 grant
DK158307C (en) 1990-10-08 grant
DK160610B (en) 1991-04-02 grant
FI822140D0 (en) grant
FI77858C (en) 1989-05-10 grant
CA1184559A (en) 1985-03-26 grant
US4639464A (en) 1987-01-27 grant
FI822140A0 (en) 1982-06-15 application
CA1184559A1 (en) grant
US4826864A (en) 1989-05-02 grant
EP0072615B1 (en) 1985-12-27 grant

Similar Documents

Publication Publication Date Title
US3293263A (en) Diphenylbenzocycloalkenes
US4478849A (en) Secondary amines, their preparation and use in pharmaceutical compositions
US4554276A (en) 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US4110337A (en) Triazolobenzodiazepines
US4241073A (en) Treatment of immediate hypersensitivity diseases with aryl hydantoins
US5132435A (en) 2-thienylglycidic derivative, process for its preparation and its use as synthesis intermediate
US4255444A (en) 4-Hydroxy-2-pyrone derivatives having antihyperlipaemic activity
US4011339A (en) Hypolipidemic allene carboxylic acids
US4002749A (en) Substituted indolinones
US4317922A (en) [(5,6,9a-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids and their analogs, esters, salts and derivatives
US3974212A (en) [1-Hydroximino-2,2-disubstituted-5-indanyloxy-(or thio)]alkanoic acids
US5081136A (en) 1,2,3-triazole compounds active as inhibitors of the enzyme hmg-coa reductase and pharmaceutical compositions containing them
US4338333A (en) Ethanamine derivatives their preparation and use in pharmaceutical compositions
US4006243A (en) Amino-, mercapto- and -oxy-substituted-phenyl and -phenalkyl imidazoles
US4078071A (en) Derivatives of substituted N-alkyl imidazoles
US4355040A (en) Hypotensive imidazole-5-acetic acid derivatives
US5451600A (en) Substituted tetrahydrobenzopyrrolylfuranoic acid derivatives as phospholipase A2 inhibitors
US4375475A (en) Substituted pyranone inhibitors of cholesterol synthesis
US3984465A (en) 1-Oxo-2,2-disubstituted-5-indanyloxy(or thio)alkanoic acids
US5300654A (en) Method for the preparation of unsaturated ketones
US4546194A (en) Substituted chromanon-2-yl alkanols and derivatives thereof
US4337354A (en) [(5,6,9a-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids, their analogs, esters, salts, and derivatives
US4792568A (en) Aryl pyrroles as useful antiallergy compounds
US4085219A (en) 1-Oxo-2,2-disubstituted-5-indanyloxy(or thio)alkanoic acids
US5216167A (en) Phenylacetic acid benzylamides

Legal Events

Date Code Title Description
AS Assignment

Owner name: FARMOS GROUP LTD., PL 425, SF-20101 TURKU 10, FINL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:KARJALAINEN, ARTO JOHANNES;KURKELA, KAUKO O. A.;REEL/FRAME:004021/0199

Effective date: 19820614

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: ORION-YHTYMA OY

Free format text: MERGER;ASSIGNOR:FARMUS-YHTYMA OY;REEL/FRAME:005635/0933

Effective date: 19890914

FPAY Fee payment

Year of fee payment: 8

PTEF Application for a patent term extension

Free format text: PRODUCT NAME: DOMITOR (MEDETOMIDINE)

Filing date: 19960510

Expiry date: 20010211

FPAY Fee payment

Year of fee payment: 12

PTEG Grant of a patent term extension

Free format text: PRODUCT NAME: DOMITOR (MEDETOMIDINE)

Filing date: 19960510

Expiry date: 20010211

Extension date: 20040211

355A Patent term extension or patent term restoration according to 35 u.s.c. 155, 155a or 156

Free format text: THREE YEARS, EXPIRES: 20010211

356 Patent term extension under 35 u.s.c. 156

Free format text: PRODUCT NAME: DOMITOR

Expiry date: 20010211

Extension date: 20040211

AS Assignment

Owner name: ORION CORPORATION, FINLAND

Free format text: CHANGE OF NAME;ASSIGNOR:ORION-YHTYMA OY;REEL/FRAME:017596/0787

Effective date: 20040401